Isolation of large numbers of human peripheral blood CD34
Peripheral blood stem cells (PBSCs) are increasingly used for autologous stem cell transplantation after high-dose chemotherapy. CD34
+ cell selection has also been done for use in autologous transplantation studies. Bone marrow (BM) may contain tumor cells at the time of harvesting and on reinfusion these cells could contribute to a subsequent relapse. [1] [2] [3] Similarly, tumor cell contamination of PBSC collections has been found in a number of studies. 4, 5 Therefore, purging of contaminating tumor cells may prove fruitful to prevent cases of relapse. Randomized clinical trials are required to address this issue. As most tumor cell types (eg multiple myeloma, breast cancer, and the majority of lymphomas) do not express the CD34 antigen, one of the most widespread applications of CD34 + cell selection is likely to be in tumor cell purging. 6 In a similar fashion, CD34
+ cell selection has aided allogeneic transplantation studies. Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality in cases of allogeneic transplantation. 7, 8 As aGVHD is mediated by donor T cells, removal of T cells from the graft by CD34
+ cell selection may ensure prophylaxis against aGVHD.
In the vast majority of studies to date, CD34 + cells have been selected from freshly collected hematopoietic cells, that is, few cryopreserved cells. [9] [10] [11] [12] We report here the feasibility of CD34 + cell selection from frozen peripheral blood stem cell concentrates, obtained by leukapheresis in the case of patients with advanced malignancies or in case of healthy adult donors, and the efficacy of these selected cells to reconstitute hematopoiesis after high-dose chemotherapy in one patient.
Materials and methods

Peripheral blood progenitor cell collection and cryopreservation
CD34
+ cell purification was performed 22 times on the whole to one-third of fresh apheresis products collected from eight patients with non-Hodgkin's lymphoma (NHL) and six normal adult volunteers. They had previously signed consent forms approved by the committee of Hokkaido University School of Medicine and Hokkaido Red Cross Blood Center for the Protection of Human Subjects. Fourteen CD34
+ cell purifications were done on one-third to one quarter of frozen apheresis products collected from eight patients with NHL, three patients with breast cancer and three normal adult donors. PBSCs were collected on the Cobe Spectra Blood Cell Processor (Cobe Laboratories, Quedgeley, UK) from patients who had received a variety of chemotherapy regimens followed by granulocyte colonystimulating factor (G-CSF). PBSCs from adult volunteers and donors were mobilized by means of a subcutaneous injection of G-CSF at a dose of 5 g/kg for 5 days, and two collections were carried out on consecutive days (days 5 and 6), for each volunteer. Cells were cryopreserved by standard institutional protocols. Briefly, the apheresis products were mixed with an equal volume of a solution consisting 4% human serum albumin (HSA), 6% hydroxyethyl starch (HES) and 5% dimethyl sulfoxide (DMSO) to yield a final cell concentration of 1 × 10 8 cells/ml. The resulting cell suspension was then divided into equal volumes and was dispensed into Hemofreeze bags (Gambro, Hechingen, Germany). The cells were cryopreserved in a controlled rate freezer (Kryo 10, Planer Products, Sunbury-on-Thames, UK) and stored until required in liquid nitrogen (liquid phase). All samples used after the death of the patients or after transplantation were acceptable. Written informed consent was obtained from all these Japanese patients and donors prior to PBSC harvest.
Thawing and cell washing procedure from frozen products
Fresh apheresis products were processed for CD34 + cell purification in Ca 2+ -, Mg
2+
-free Dulbecco's phosphate buffered saline (D-PBS) containing 1% HSA at room temperature (25°C) (1% HSA at 25°C), as reported. 13 However, the same purification procedure lead to aggregate formation by cells from the cryopreserved apheresis products. We therefore examined the effects of various concentrations of HSA and temperature to prevent such aggregate formation. Cryopreserved products were thawed and washed twice in the following concentrations of HSA and different temperatures (4% HSA at 4°C, 1% HSA at 4°C, 4% HSA at 25°C, 1% HSA at 25°C) and thawed samples were counted. These thawed and washed cells were resuspended under each condition, and cell numbers were counted after thawing and washing at 1, 2 and 3 h. Treatment of cells in PBS containing 4% HSA at 4°C significantly prevented aggregate formation than did other conditions, and suspension at room temperature led to the formation of irreversibly aggregated or clumped cells (Table 1) . Therefore, we used PBS containing 4% HSA at 4°C to purify CD34 + cells from cryopreserved products and 1% HSA at 25°C from fresh products.
Purification of CD34
+ cells using immunomagnetic microspheres
The cryopreserved peripheral blood cells in Hemofreeze bags were recovered by rapid thawing in a 37°C waterbath. These thawed cells suspended in 4% HSA at 4°C were washed twice by centrifugation at 450 g for 5 min at 4°C. The platelets were removed twice by overlaying on 10% HSA and centrifugation at 450 g for 15 min at 4°C (Plcells). The erythrocytes were removed by overlaying on Ficoll-Hypaque (FH; 1.077 g/cm 3 ; Pharmacia Fine Chemicals, Piscataway, NJ, USA) and centrifugation at 400 g for 25 min at 4°C. The interface mononuclear cells (Pl−, FH cells) were collected, washed twice in washing solution and resuspended in 4% HSA at 4°C (MN cells).
A nylon-fiber syringe (NF-S) was used to remove adherent cells, as reported. 13, 14 Five grams of NF (Wako Pure Chemical Industries, Osaka, Japan) was packed into a 50 ml disposable syringe (Terumo, Tokyo, Japan). The MN cells were transferred to an additional 50 ml syringe and gently infused into the NF-S, then were incubated at 4°C for 5 min. The MN cells were then collected into a 50 ml syringe through a plunger of the NF-S, and the cells were pooled in 50 ml of a conical tube (collection tube; Becton Dickinson). These pooled cells were centrifuged at 400 g for 5 min at 4°C, and resuspended in 4% HSA at 4°C (NF cells).
The cell suspension was then immediately processed for CD34 + selection on the Isolex Magnetic Cell Separation System (Isolex 50; Baxter Healthcare, Immunotherapy Division, Newbury, UK) following the manufacturer's instructions. Briefly, cells were incubated with 9C5 murine immunoglobulin G 1 (IgG 1 ) anti-human CD34 antibody (10 g/1 × 10 8 NF cells) for 15 min at 4°C with slow endover-end rotation. After sensitization, the cells were washed with 4% HSA at 4°C to remove any excess/unbound antibody. The Dynabeads (Oslo, Norway) were then added to the washed, sensitized cells at a final bead/cell ratio of 1:10. After mixing at 4°C for 30 min, the cell-bound microspheres and free microspheres became attached to the wall via the magnet (Dynal MPC-1, Dynal, Fort Lee, NJ, USA) and any free cells that did not bind to the microspheres were removed. This washing procedure was repeated twice with 4% HSA at 4°C. The linkage between Dynabeads and CD34 + cells was cleaved by a PR34 + Stem Cell Releasing Agent for 30 min at 4°C. The free Dynabeads were removed from the CD34 + cells via the magnet. For this purification of fresh products, we used D-PBS containing 1% ACD-A and 1% HSA at 25°C instead of 4% HSA at 4°C, as reported earlier. 13 
Refreezing/thawing of CD34
+ cells
The CD34 + cells purified from fresh and cryopreserved products were transferred into sterile polypropylene tubes containing 4% HSA, 6% HES and 5% DMSO to yield a final cell concentration of between 2 and 10 × 10 7 cells/ml. The tubes containing CD34 + cells were placed in a freezer at −80°C. After overnight freezing for 20-24 h, the tubes containing CD34
+ cells were stored in liquid nitrogen. The frozen CD34
+ cells were thawed rapidly in a 37°C waterbath, suspended in Iscove's modified Dulbecco's medium (IMDM) containing 30% fetal calf serum (FCS), and centrifuged at 400 g for 5 min at 4°C. The cells were washed twice with IMDM containing 20% FCS and then resuspended in IMDM containing 0.3% deionized bovine serum albumin (BSA). Cell numbers and viability were determined by trypan blue dye-exclusion. Clonogenic assays were done and clonogenicity of the CD34 + cells before and after cryopreservation was compared.
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1%HSA, 25°63.9 ± 5.3 58.6 ± 5.9 55.2 ± 3.7 50.6 ± 0.9
Mean ± SD of three individual experiments of recovery after thawed frozen-apheresis products.
Cryopreserved products were thawed, washed and counted as described under Materials and methods. 
Flow cytometry
Flow cytometry on FACS calibur (Becton Dickinson, Mountain View, CA, USA) was done as described elsewhere, 15 and data were collected, with logarithmic amplification. 14 
Culture of fractionated cells
The P1− cells, the NF cells, cells in the CD34 + fraction and refrozen/thawed CD34 + cells were incubated in triplicate at a concentration of 2 × 10 5 cells/ml for MN and NF cells, 300 cells/ml for the cells in the CD34 + fractions. The cells were cultured in flat-bottomed 24-well tissue culture plates (Linbro; Flow Laboratories) with a 0.5 ml serum-containing fibrin clots, as described. 15 The culture medium included IMDM containing 20% FCS, 10% pooled human AB serum, 1% deionized bovine serum albumin (BSA; Sigma, St Louis, MO, USA; Cohn fraction V), 5 × 10 −5 mol/l 2-mercaptoethanol (2-ME; Sigma), 1.5 mmol/l ⑀-aminocaproric acid (EACA; Kishida Chemical Co, Osaka, Japan), penicillin at 50 U/ml, streptomycin at 50 U/ml (Flow Laboratories, McLean, VA, USA), 10 g/ml insulin, 2 U/ml of recombinant human (rh) erythropoietin (rEP; 180 000 U/mg; Chugai Pharmaceutical, Tokyo, Japan), 50 U/ml of rh interleukin-3 (rIL-3; 10 8 CML U/mg; Amgen Biologicals, Thousand Oaks, CA, USA), 50 U/ml of rh granulocyte-macrophage colony-stimulating factor (rGM-CSF; 4.5 × 10 7 U/mg; Schering Research, Bloomfield, NJ, USA),
Bone Marrow Transplantation 50 ng/ml of rh granulocyte-CSF (Chugai Pharmaceutical), 2 mg/ml human fibrinogen (Sigma), 0.2 U/ml thrombin (Parke-Davis, Morris Plains, NJ, USA). After 14 days of incubation at 37°C in a 5% CO 2 atmosphere, the clots were fixed and benzidine-hematoxylin or May-Grünwald staining was done. The enumeration of burst-forming uniterythroid (BFU-E) and erythroid-mix was done in accordance with the criteria of Clarke and Housman. 16 Colonies that gave rise to 40 or more nonhemoglobinized cells were counted as being non-erythroid.
Differences between groups of data were analyzed with the Scheffe's F and Fisher's PLSD post hoc test, with P Ͻ 0.05 taken as a significant difference.
Transplant procedure
A 49-year-old Japanese woman was given a diagnosis of low-grade non-Hodgkin's lymphoma (NHL) stage IV (bone marrow (BM), and ascites due to lymphoma invasion). phamide i.v. on days −3 and −2 (total dose 100 mg/kg) (MCVC regimen), as reported. 17 On day 0, CD34 + cells were purified from cryopreserved products and infused into the patient. G-CSF (5 g/kg subcutaneously) was administered from day 1 until granulocyte recovery.
Results
Comparison of CD34
+ cell purification from fresh and cryopreserved apheresis products
The whole to one-third of fresh apheresis products had a mean (±s.d.) white cell count of 2511 ± 1822 × 10 7 cells with a CD34
+ cell content of 1.1 ± 0.7%, and one-third to one quarter of cryopreserved apheresis products had 1511 ± 688 × 10 7 cells with CD34 + cell content of 1.3 ± 0.6%. Numbers of CD34 + cells remaining after each stage of processing are given in Table 2 . There was a trend toward greater CD34
+ cell loss at each stage of processing for cryopreserved samples as compared with fresh samples. Cell clumping was a consistent problem after thawing and contributed to cell losses due to cryopreservation, as macroscopic clumps were not included in cell counting. After CD34 + cell purification, the final yield of CD34 + cells compared with Pl− cells was 37.2 ± 24.1% for fresh specimens. This seemed to decrease to 23.9 ± 13.2% for samples purified after cryopreservation, but with no statistical significance ( Table 2) . Purity of CD34 + cells was greater when performed on fresh specimens than when cryopreserved cells were used (94.6 ± 10.0% vs 85.9 ± 14.4%, P Ͻ 0.05). There was no significant difference in recovery of colonyforming progenitor cells among CD34 + cells purified from fresh and cryopreserved products (total colonies: 17.5 ± 10.1% vs 14.4 ± 5.7%, CFU-GM: 30.1 ± 18.4 vs 22.6 ± 13.5%, BFU-E: 11.6 ± 9.4% vs 16.8 ± 19.2%) (Figure 1) .
The main subpopulations of CD34 + cells purified from cryopreserved products were CD13 + cells (89.1%). The incidence of co-expression of CD38 or CD41 on progenitor was 71.9% or 5.5%, respectively (Table 3) . These subpopulations of CD34 + cells purified from frozen products were comparable in number to those seen in the previous results from fresh products.
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Table 2
Recovery of CD34 + cells from frozen and fresh apheresis products 
Cells Frozen apheresis products (n = 14) Fresh apheresis products (n = 22)
Total cells CD34
Table 3
Phenotypic subpopulations of purified CD34 + cells from fresh and frozen apheresis products
Products
Purity of Subsets of CD34
Fresh (n = 6) 93.7 ± 8.1 94.0 ± 5.1 65.3 ± 13.6 2.9 ± 2.0 Frozen (n = 8) 88.5 ± 14.4 71.9 ± 31.6 89.1 ± 13.8
5.5 ± 6.3
Mean ± s.d. of six individual experiments of CD34 + cell from fresh products, and eight individual experiments using frozen products. CD34 + cells were purified using immunomagnetic microspheres, as described under Materials and methods.
Recovery of frozen/thawed CD34 + cells purified from fresh and cryopreserved apheresis products
The mean nucleated cell recovery after freeze/thawing of the enriched CD34 + cells, as purified from fresh and cryopreserved products, was 76.6 ± 21.2% and 64.1 ± 24.2%, with no statistically significant difference (Figure 2) . The mean viability, 85.1 ± 7.9%, of the refrozen/thawed CD34 + cells from cryopreserved products was lower than the frozen/thawed CD34 + cells from fresh products with a viability of 94.7 ± 4.1% (P Ͻ 0.001).
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Colony forming rate re-frozen/thawed CD34 + cells purified from cryopreserved products
Clonogenic assays of the CD34
+ cells purified from cryopreserved products (n = 15) before and after cryopreservation were done. As shown in Figure 3 , the colony-forming cell frequencies (colony-forming cells/100 viable cells × 100) of CD34 + cells purified from cryopreserved products was significantly lower after thawing than before freezing (20.2 ± 9.4% vs 27.4 ± 5.6%: P Ͻ 0.05). + cells, before refreezing and after thawing.
Hematopoietic recovery after transplantation of CD34
Bone Marrow Transplantation using the purification procedure described here. Table 4 summarizes the characteristics of the graft. Hematopoietic recovery was evident: 1000 WBC/mm 3 on day 12, 500 neutrophils/mm 3 on day 11, 1000 neutrophils/mm 3 on day 12, first reticulocytosis on day 17, 50 000 platelets/mm 3 on day 21. A number of 100 000 platelets/mm 3 was never attained during follow-up. She was given 2000 ml RBC and 120 units platelet concentrates during the entire procedure. A partial remission (residual small lymph node swelling around the aorta abdominalis) was obtained after peripheral blood CD34 + cell transplantation, and this patient is well with no sign of progressive disease 10 months after this treatment.
Discussion
We report here the feasibility of positive CD34
+ cell selection from cryopreserved peripheral blood mononuclear cell concentrates, obtained by leukapheresis from patients with advanced malignancies treated with chemotherapy and G-CSF or normal adult donors with G-CSF only, and the efficacy of these selected cells to reconstitute hematopoiesis after myeloablative chemotherapy in one patient.
The feasibility of positive selection of CD34 + cells from PBSC or bone marrow before cryopreservation was noted when using the CellPro (Bothell, WA, USA) Ceprate system or immunomagnetic beads. [18] [19] [20] [21] These methods allow for selection of a single or two PBSC concentrates obtained at a 24-h interval, the first leukapheresis concentrate being preserved overnight at 4°C, pooled with the second one and washed with washing solution prior to the selection procedure. This selection strategy is not feasible for patients who require more than two sessions of leukapheresis and for selection after detection of tumor cells in apheresis products by Southern blot analysis of gene re-arrangement or PCR analysis.
The formation of clumps was the major problem encountered during the procedure of CD34 + cell selection from cryopreserved PBSC, using PBS containing 1% HSA at room temperature, but success was attained for CD34 + cell purification from fresh apheresis products. Thus, the formation of clumps was a contributing factor to low recovery 
PB CD34
+ cells from apheresis products of an autologous donor with NHL were purified as described above. The CD34 + cells were purified using one kit of Isolex per cryopreserved product. and low purity of purified CD34 + cells from cryopreserved products. Other authors reported CD34 + cell purification from cryopreserved apheresis products, and various conditions (salt solution containing 1% HSA at 4°C, salt solution containing 1% HSA at room temperature, PBS containing 4% HSA at room temperature and PBS containing 4% HSA at 4°C) were used. [9] [10] [11] [12] In a report by Alcorn et al, 11 who used salt solution containing 1% HSA at 4°C, a contributing factor to low CD34 + cell recoveries was the concentration at which the cells were cryopreserved. Bohbot et al 9 reported that the use of PBS at 4°C or at room temperature leads to formation of irreversibly aggregated or clumped cells and induces continuous lysis of cells with generation of free DNA. Platelet clumps may relate to an activation of platelets during the thawing process, which is strongly attenuated in 4% HSA and at 4°C. At 4°C and using 4% HSA during the washing steps the MoAb labeling procedure prevents clump formation and cell loss. When we examined the effects of various concentrations of HSA and temperature to prevent aggregate formation (4% HSA at 4°C, 1% HSA at 4°C, 4% HSA at 25°C, 1% HSA at 25°C), we found that treatment of cells in PBS containing 4% HSA at 4°C prevents aggregate formation and suspension at room temperature led to the formation of irreversibly aggregated or clumped cells. Despite use of PBS containing 4% HSA at 4°C, some degree of cell clumping was observed, but was acceptably low in the most cases.
In our report, the purity of CD34 + cells from cryopreserved products was significantly lower than in the case of fresh products, probably due to some degree of cell clumping (purity: 85.9 ± 14.4% vs 94.6 ± 10.0%). However, no statistically significant differences were observed in the recovery of CD34 + cells and colony-forming progenitor cells of purified cells from fresh and cryopreserved products, as shown in Table 2 and Figure 1 . Therefore CD34 + cells purified from cryopreserved products can be used clinically. Our clinical data show that CD34 + cells purified from cryopreserved apheresis products may be capable of reconstituting hematopoiesis after myeloablative chemotherapy. The recovery of neutrophils and red cells was prompt as was that of unmodified frozen PBSCs in our institution or a previously selected CD34 + fraction. 17, 22, 23 Delayed mild thrombocytopenia may occur after autologous transplant, especially for disease with previous marrow involvement and cytomegalovirus (CMV) infection. If refrozen/thawed CD34 + cells purified from cryopreserved products could be used for transplantation, it would be possible to start the myeloablative chemotherapy after confirming the number of CD34 + cells purified from cryopreserved products. When we could not purify enough CD34 + cells, one more leukapheresis and CD34
+ cells purification could be carried out. Therefore we examined whether CD34 + cells selected from freeze/thawed samples can be again frozen and thawed for analysis. The viability of the refrozen/thawed CD34 + cells from cryopreserved products was lower than from fresh products, and the colony-forming efficiency of CD34 + cells purified from cryopreserved products was significantly lower after thawing than before freezing. In our patient, purified CD34 + cells accounted for 1.97 × 10 6 cells/kg. Nachbaur et al 24 reported that time to leukocyte and platelet recovery was significantly shorter in patients given Ͼ2.0 × 10 6 cells/kg purified CD34 + cells, as compared to patients reinfused with Ͻ2.0 × 10 6 cells/kg CD34 + cells. About 30% of refrozen/thawed CD34 + cells from frozen products was lost, as compared with fresh products, when calculated by the viability and colony-forming efficiency (Figures 2 and 3) . Therefore, purified CD34 + cells from cryopreserved products were not frozen and were directly transfused to our patient. If one could obtain Ͼ3.0 × 10 6 cells/kg purified CD34 + cells, refrozen/thawed CD34 + cells from cryopreserved products may be applicable for clinical use because these cells demonstrated a good proliferative capacity in our laboratory-scale investigations of hematopoiesis. 25, 26 In our previous study, using a nylon-fiber syringe system (NF-S) and immunomagnetic microspheres, a consistent high purity of CD34 + cells in the purified population and cost reduction were achieved. 13 In the present study, we used about 5 g of anti-CD34 MAb (9C5) for 1 × 10 8 Pl− cells and depletion of monocytes by NF-S reduced the 9C5 required for purification of CD34 + cells to one-fifth of manufacturer's instructions and without NF-S. Our data show that these purified CD34
+ cells from cryopreserved products are capable of rapidly reconstituting hematopoiesis after myeloablative chemotherapy. Peripheral blood CD34
+ cell transplantation using our purification procedures may prove feasible for even larger numbers of patients.
